Clinical trial · Observational
AI-based Measurements of Tumour Burden in PSMA PET-CT
The Prognostic Value of AI-based Measurements of Tumour Burden in PSMA PET-CT in Patients With Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary aim of the present study is to evaluate how automatically calculated (by an AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x SUVmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as the total tumour burden predicts overall survival (OS) in patients with prostate cancer (newly diagnosed and patients with biochemical recurrence).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with prostate cancer
- description
- Patients referred to clinically indicated PSMA PET-CT due to initial or secondary staging of prostate cancer
- interventionNames
- Device: AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans
Primary outcomes (1)
- measure
- Tumour burden (cm3) in relation to overall survival
- timeFrame
- 5-year follow-up
- description
- Evaluate how the total tumour burden (cm3) predicts overall survival (OS). The total tumour burden will automatically be calculated by the AI-based method and will through Cox regression analysis be related to OS
Secondary outcomes (4)
- measure
- Tumour burden (cm3) in relation to biochemical recurrence
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 20 Years
- Maximum age
- 120 Years
Show eligibility criteria text
Inclusion Criteria: * Patients referred to a clinically indicated 18F-PSMA-1007 PET-CT scan at Skåne University Hospital, Lund or Malmö, Sweden Exclusion Criteria: * Patients under 20 years old
References
Publications (0)
Data not yet available